Ergomed Aktie kaufenswert? (Seite 20)
eröffnet am 01.12.16 16:57:13 von
neuester Beitrag 04.09.23 10:24:12 von
neuester Beitrag 04.09.23 10:24:12 von
Beiträge: 415
ID: 1.242.462
ID: 1.242.462
Aufrufe heute: 0
Gesamt: 19.692
Gesamt: 19.692
Aktive User: 0
ISIN: GB00BN7ZCY67 · WKN: A117XM
15,480
EUR
+0,06 %
+0,010 EUR
Letzter Kurs 08.11.23 Lang & Schwarz
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5800 | +922,86 | |
| 0,5400 | +38,46 | |
| 1,9900 | +32,67 | |
| 5,4000 | +27,06 | |
| 1,8250 | +25,86 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,0100 | -26,54 | |
| 14,510 | -32,32 | |
| 3,6400 | -38,62 | |
| 0,5660 | -40,42 | |
| 84,75 | -74,50 |
Beitrag zu dieser Diskussion schreiben
Feedback
Gemächlich aufwärts - zu den 10 Euro 
Why choose Ergomed and PSR Orphan Experts for your next #RareDisease clinical trial?
• Pioneers in rare disease drug development
• Genuine family and patient centricity
• Global reach and access to patients with rare and ultra-rare diseases
• Very strong Regulatory Group which can map the most optimal regulatory strategy and support your EMA/FDA interactions
• Close collaboration with #patientadvocacy groups maximizing our partners’ success
• #Orphandisease toolkit to reduce the patient and family burden
• Dedicated Site Support Group to support site-staff with complex study logistics
• Experience with a wide range of indications and study drugs, including #AdvancedTherapy products
We are proud to have gained the trust of our clients by providing innovative and creative solutions that ensure successful Rare Disease clinical trials.
To find out more about PSR Orphan Experts, an Ergomed company, please visit https://lnkd.in/eSDmW9D
• Pioneers in rare disease drug development
• Genuine family and patient centricity
• Global reach and access to patients with rare and ultra-rare diseases
• Very strong Regulatory Group which can map the most optimal regulatory strategy and support your EMA/FDA interactions
• Close collaboration with #patientadvocacy groups maximizing our partners’ success
• #Orphandisease toolkit to reduce the patient and family burden
• Dedicated Site Support Group to support site-staff with complex study logistics
• Experience with a wide range of indications and study drugs, including #AdvancedTherapy products
We are proud to have gained the trust of our clients by providing innovative and creative solutions that ensure successful Rare Disease clinical trials.
To find out more about PSR Orphan Experts, an Ergomed company, please visit https://lnkd.in/eSDmW9D
See you at the World Orphan Drug Congress USA 2020 Virtual Event
https://www.ergomedplc.com/see-you-at-the-world-orphan-drug-…
https://www.ergomedplc.com/see-you-at-the-world-orphan-drug-…
Ergomed : fully compliant under MyData Trust's label 'Good Data Protection Practice'
https://www.marketscreener.com/quote/stock/ERGOMED-PLC-16917…
https://www.marketscreener.com/quote/stock/ERGOMED-PLC-16917…
... und nochmal weiter rauf.
Trading Spotlight
In London ging es weiter nach oben... ATH... aber sicher noch lange nicht das Ende. Bislang findet der Wert bei uns ja kaum Beachtung.
Ergomed - executive interview
In this interview, Ergomed's CFO Richard Barfield runs through:
- The highlights of Ergomed’s recent trading update, with total H120 revenues increasing by 14.8% to £40.4m.
- How Ergomed has demonstrated significant resilience through the COVID-19 crisis.
- Some of the reasons behind the startling growth in Ergomed’s revenues over the last three years and how it intends to maintain that momentum.
- An overview of Ergomed’s M&A strategy.
- The outlook towards upcoming newsflow.
Ergomed is a global full-service CRO business with a core focus on the US and EU. It provides Phase I–III clinical services in addition to post-marketing pharmacovigilance (Phase IV) services through its PrimeVigilance division. The company is predominantly focused on oncology, orphan drugs, rare diseases and pharmacovigilance.
In this interview, Ergomed's CFO Richard Barfield runs through:
- The highlights of Ergomed’s recent trading update, with total H120 revenues increasing by 14.8% to £40.4m.
- How Ergomed has demonstrated significant resilience through the COVID-19 crisis.
- Some of the reasons behind the startling growth in Ergomed’s revenues over the last three years and how it intends to maintain that momentum.
- An overview of Ergomed’s M&A strategy.
- The outlook towards upcoming newsflow.
Ergomed is a global full-service CRO business with a core focus on the US and EU. It provides Phase I–III clinical services in addition to post-marketing pharmacovigilance (Phase IV) services through its PrimeVigilance division. The company is predominantly focused on oncology, orphan drugs, rare diseases and pharmacovigilance.
und wieder geht es ein Stückchen weiter hoch....
Antwort auf Beitrag Nr.: 64.750.360 von JohnAsh am 13.08.20 14:37:56
Solche vergleiche hinken zwar immer etwas aber trotzdem steht Ergomed eine erfolgreiche Zukunft bevor.
Gruß
Value
Zitat von JohnAsh: Eben, sehr gut - die neue evotec.... 👍
Solche vergleiche hinken zwar immer etwas aber trotzdem steht Ergomed eine erfolgreiche Zukunft bevor.
Gruß
Value
Eben, sehr gut - die neue evotec.... 👍
Durchsuchen
